Julia Meyer

Julia Meyer

Auto-generated profile, based on publicly available information

Julia Meyer

University of California San Francisco 20 Department of Pediatrics, Benioff Children’s Hospitals San Francisco, California

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2022 in BMC Medicine
Verified
Journal Article
Open access
PDF file
Tomabu AdjobimeyTomabu Adjobimey
Tomabu Adjobimey
JMJulia Meyer
Julia Meyer
VTVedrana Terkeš
Vedrana Terkeš
MPMarijo Parcina
Marijo Parcina
Achim M. HöraufAchim M. Hörauf
Achim M. Hörauf
Background: The coronavirus disease 2019 (COVID-19) is a respiratory disease caused by SARS-CoV-2, a recently discovered strain of coronavirus. The virus has spread rapidly, causing millions of death worldwide. Contrary to the predictions, prevalence and mortality due to COVID-19 have remained moderate on the African continent. Several factors, including age, genetics, vaccines, and co-infections, might impact the course of the pandemic in Africa. Helminths are highly endemic in Sub-Saharan Africa and are renowned for their ability to evade, skew, and suppress human immune responses through various immune-modulatory mechanisms. Such effects will likely impact SARS-CoV-2 transmission and disease progression. Methods: Here, we analyzed in vitro the impact of antigen extracts from three major helminth parasites, including Onchocerca volvulus, Brugia malayi, and Ascaris lumbricoides, on the immune reactivity to SARS-CoV-2 peptides in COVID-19 patients. Activation of CD4+ and CD8+ T cells was investigated using flow cytometry to monitor the expression of CD137 (4-1BB) and CD69. Cytokine expression, including IL-6, IL-10, IFN-γ, and TNFα, was measured by Luminex in cell culture supernatants. Results: We observed that helminth antigens significantly reduced the frequency of SARS-CoV-2-reactive CD4+ T helper cells. In contrast, the expression of SARS-CoV-2-reactive CD8+ T cells was not affected and even significantly increased when PBMCs from COVID-19 patients living in Benin, an endemic helminth country, were used. In addition, stimulation with helminth antigens was associated with increased IL-10 and a reduction of IFNγ and TNFα. Conclusions: Our data offer a plausible explanation for the moderate incidence of COVID-19 in Africa and support the hypothesis that helper T cell-mediated immune responses to SARS-CoV-2 are mitigated in the presence of helminth antigens, while virus-specific cytotoxic T cell responses are maintained.

11 June 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ESElliot Stieglitz
Elliot Stieglitz
ALAlex G. Lee
Alex G. Lee
SASteven P. Angus
Steven P. Angus
CDChristopher Davis
Christopher Davis
DBDonald A. Barkauskas
Donald A. Barkauskas
BWBrenda J. Weigel
Brenda J. Weigel
Juvenile myelomonocytic leukemia (JMML) is a hematologic malignancy of young children caused by mutations that increase Ras signaling output. Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment, but patients with relapsed or refractory (advanced) disease have dismal outcomes. This phase II trial evaluated the safety and efficacy of trametinib, an oral MEK1/2 inhibitor, in patients with advanced JMML. Ten infants and children were enrolled, and the objective response rate was 50%. Four patients with refractory disease proceeded to HSCT after receiving trametinib. Three additional patients completed all 12 cycles permitted on study and continue to receive off-protocol trametinib without HSCT. The remaining three patients had progressive disease with two demonstrating molecular evolution by the end of cycle 2. Transcriptomic and proteomic analyses provided novel insights into the mechanisms of response and resistance to trametinib in JMML. ClinicalTrials.gov Identifier: NCT03190915. Significance: Trametinib was safe and effective in young children with relapsed or refractory JMML, a lethal disease with poor survival rates. Seven of 10 patients completed the maximum 12 cycles of therapy or used trametinib as a bridge to HSCT and are alive with a median follow-up of 24 months. See related commentary by Dankyi and Padron, p. 1574

5 December 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
MHMark Hartmann
Mark Hartmann
MSMaximilian Schönung
Maximilian Schönung
JRJovana Rajak
Jovana Rajak
VMValentin Maurer
Valentin Maurer
LHLing Hai
Ling Hai
DLDaniel Lipka
Daniel Lipka
Persistent fetal gene expression in childhood neoplasms is usually explained by a maturation block originating in the prenatal phase. In contrast, reactivation of fetal genes in adult malignancies is considered a consequence of oncofetal reprogramming (OFR) and is associated with aggressive disease. By reconstructing epigenetic ontogeny in juvenile myelomonocytic leukemia (JMML), we identified a postnatal maturation state of JMML stem cells with high transcriptional plasticity indicative of OFR in high-risk disease. Similarly, postnatal activation of oncogenic signaling by inducible Ptpn11E76K mutation in mice triggered molecular plasticity and reactivation of fetal gene expression. Integrative multi-omics analysis revealed aberrant CD52 expression as a feature of high-risk JMML stem cells. Anti-CD52 treatment depleted JMML stem cells and blocked disease propagation in xenograft models. Our results challenge the prevailing maturation block model of pediatric leukemogenesis and establish RAS-associated stem cell plasticity as a determinant of OFR and potential therapeutic vulnerabilities in high-risk JMML. Significance: Persistent fetal gene expression in pediatric malignancies is considered a consequence of prenatal maturation blockade. In this study, we demonstrate that oncogenic PTPN11 mutations enhance cellular plasticity. This leads to partial restoration of fetal molecular programs, creating new therapeutically exploitable vulnerabilities. See related commentary by Miao and Xu, pp. 168

31 August 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
JMJulia A. Meyer
Julia A. Meyer
SXSherin Xirenayi
Sherin Xirenayi
JWJuwita Werner
Juwita Werner
RTRust Turakulov
Rust Turakulov
AHAaron Hechmer
Aaron Hechmer
AEAlaa Elhaddad
Alaa Elhaddad

4 September 2024
Verified
Other
Open access
PDF file
ESElliot Stieglitz
Elliot Stieglitz
ALAlex G. Lee
Alex G. Lee
SASteven P. Angus
Steven P. Angus
CDChristopher Davis
Christopher Davis
DBDonald A. Barkauskas
Donald A. Barkauskas
BWBrenda J. Weigel
Brenda J. Weigel
Supplementary Figure S2. Supplementary Figure S2. Kinome profiling. The sum of each kinase log2 fold change for each individual patient (post-vs. pretreatment) was determined and plotted using the Coral web tool (http://phanstiel-lab.med.unc.edu/CORAL/) with branch and node color scaled as indicated and node size scaled according to the absolute fold change sum.

17 June 2026
Verified
Other
Open access
ESElliot Stieglitz
Elliot Stieglitz
ALAlex G. Lee
Alex G. Lee
SASteven P. Angus
Steven P. Angus
CDChristopher Davis
Christopher Davis
DBDonald A. Barkauskas
Donald A. Barkauskas
BWBrenda J. Weigel
Brenda J. Weigel
Qualitative and Quantitative Summary of Abnormal Peripheral Blood and Bone Marrow Findings.